Research Topics
Species | J F DonohueSummaryAffiliation: University of North Carolina Country: USA Publications
| Collaborators
|
Detail Information
Publications
Minimal clinically important differences in COPD lung functionJames F Donohue
Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, CB 7020, 4125 Bioinformatics Building, Chapel Hill, North Carolina 27599 7020, USA
COPD 2:111-24. 2005..Also distributional/statistical methods may be useful in determining the MCID FEV1...- New combination therapies for asthmaJ F Donohue
Pulmonary Division, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
Curr Opin Pulm Med 7:62-8. 2001..Many other combination therapies are presently being tested... 
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary diseaseJames F Donohue
Division of Pulmonary Disease and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Int J Chron Obstruct Pulmon Dis 6:35-45. 2011..The impact of these many variables on clinical trial results is explored, with a particular focus on changes in inclusion criteria and patient baseline demographics...
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label studyJames F Donohue
School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7020, USA
Clin Ther 30:989-1002. 2008..Moreover, it is not clear how the different dosing regimens affect symptom outcomes and health status in hospitalized patients with asthma or COPD...- Safety and efficacy of beta agonistsJames F Donohue
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
Respir Care 53:618-22; discussion 623-4. 2008..The effect of the beta receptor genotype on beta agonist response is unclear but could hold promise for proper patient management... - Evaluation of the efficacy and safety of levalbuterol in subjects with COPDJames F Donohue
University of North Carolina School of Medicine at Chapel Hill, USA
COPD 3:125-32. 2006.... - Combination therapy for chronic obstructive pulmonary disease: clinical aspectsJames F Donohue
Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, 4125 Bioinformatics Building, CB 7020, Chapel Hill, NC 27599 7020, USA
Proc Am Thorac Soc 2:272-81; discussion 290-1. 2005..Effects on survival are less clear. Some of the other issues to be resolved are the safety of combination therapy, its pharmacoeconomic impact, and the role of newer agents... - Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary diseaseJames F Donohue
Department of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 4125 Bioinformatics Bldg, CB 7020, Chapel Hill, NC 27599 7020, USA
Proc Am Thorac Soc 1:152-60. 2004..Some evidence suggests that patients with COPD who respond to corticosteroids have eosinophilic inflammation and other attributes of an asthma phenotype... - Still looking for answers in COPDJames F Donohue
Division of Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Lancet 365:1518-20. 2005 - Therapeutic responses in asthma and COPD. BronchodilatorsJames F Donohue
Division of Pulmonary Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Chest 126:125S-137S; discussion 159S-161S. 2004..The roles of stereoisomers, leukotriene receptor antagonists, and type 4 phosphodiesterase inhibitors in asthma and COPD remain uncertain at this time... - A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolJames F Donohue
Division of Pulmonary Medicine, University of North Carolina, Chapel Hill, NC 27599 7020, USA
Chest 122:47-55. 2002..A trial was designed to examine the efficacy and safety of both compounds with multiple outcome measures, including lung function, dyspnea, and health-related quality of life (HRQoL) in patients with COPD... - A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPDJames F Donohue
Division of Pulmonary Medicine, University of North Carolina, Chapel Hill, 27599 7020, USA
Treat Respir Med 3:173-81. 2004..This is the first comparison of two combination therapies, fluticasone propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of patients with COPD... - Tolerance to bronchodilating effects of salmeterol in COPDJ F Donohue
University of North Carolina School of Medicine, 130 Mason Farm Road, CB 7020 4125 Bioinformatics Bldg, Chapel Hill, NC 27599, USA
Respir Med 97:1014-20. 2003..In conclusion, tolerance to pharmacologic bronchodilation occurs with long-acting beta-agonists such as salmeterol and not with inhaled anticholinergics... - Role of bronchodilators in chronic obstructive pulmonary diseaseMax M Weder
Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
Semin Respir Crit Care Med 26:221-34. 2005..None of the bronchodilators have been shown to change outcome in COPD, but this issue is under active investigation... - Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and toleranceJ F Donohue
University of North Carolina School of Medicine, Chapel Hill, NC, USA
Ther Adv Respir Dis 2:37-48. 2008..The study also examined the occurrence of tolerance with these agents, i.e. whether improvement in airway function diminished or frequency of exacerbations increased with 12-months of use... - Nontuberculous mycobacteria in women, young and oldWorakij Chalermskulrat
Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, 420 Burnett Womack Building, CB 7020, Chapel Hill, NC 27599 7020, USA
Clin Chest Med 23:675-86. 2002..Studies exclusive to LWS are lacking and are absolutely necessary as they will enhance our understanding of, and hence successful management strategies for, this increasingly recognized disease... - Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trialJames F Donohue
University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, 27599, USA
Ther Adv Respir Dis 2:199-208. 2008..We conclude that nebulized formoterol fumarate twice daily is well tolerated over long-term treatment in moderate-to-severe COPD subjects and has a similar safety profile to the DPI formulation... - Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumJames F Donohue
University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
Am J Respir Crit Care Med 182:155-62. 2010..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)... - Accuracy of float testing for metered-dose inhaler canistersTina Penick Brock
School of Pharmacy, University of North Carolina Chapel Hill, 27599 7560, USA
J Am Pharm Assoc (Wash) 42:582-6. 2002..To characterize and evaluate canister floating patterns of three commercially available metered-dose inhalers (MDIs) with varying amounts of medication remaining... - Long-acting beta-agonists role in asthma managementJames F Donohue
Division of Pulmonary Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA
J Fam Pract . 2006..The NHLBI/NAEPP guidelines recommend inhaled corticosteroids as the first step in controller therapy, with LABAs as an option if low- to medium-dose inhaled corticosteroids do not adequately control the patient's asthma"... - Ambrisentan for sarcoidosis associated pulmonary hypertensionM A Judson
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, USA
Sarcoidosis Vasc Diffuse Lung Dis 28:139-45. 2011..Sarcoidosis associated pulmonary hypertension (SAPH) is associated with significant morbidity and mortality. There is a paucity of information concerning therapy for this condition... - The Sarcoidosis Health Questionnaire: a new measure of health-related quality of lifeChristopher E Cox
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Am J Respir Crit Care Med 168:323-9. 2003..The SHQ alone was sensitive to differences in HRQL based on the number of involved organ systems. In conclusion, we have developed a self-completed HRQL questionnaire for U.S. patients with sarcoidosis... - Health-related quality of life of persons with sarcoidosisChristopher E Cox
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA
Chest 125:997-1004. 2004..To describe the health-related quality of life (HRQL) and mental health of persons with sarcoidosis, as well as to assess physician-patient agreement about the presence of sarcoidosis symptoms... - Effect of salmeterol on mucociliary and cough clearance in chronic bronchitisWilliam D Bennett
Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina at Chapel Hill, 27599, USA
Pulm Pharmacol Ther 19:96-100. 2006..17 +/- 10 for salmeterol vs. placebo (P = 0.05 by paired analysis). Thus, in addition to its bronchodilating effects, salmeterol acutely enhances peripheral airway clearance of secretions in mild-moderate chronic bronchitis... - Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary diseaseThaw Sint
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Inhal Toxicol 20:25-9. 2008..To provide a greater awareness of PM levels, the U.S. Environmental Protection Agency now includes levels of air pollution particles in an air quality index... - Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilatorsNicola A Hanania
Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, Texas 77030, USA
Proc Am Thorac Soc 4:526-34. 2007..Several novel bronchodilators are now in different stages of development for use alone or in combination with other agents... - The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary diseaseStephen I Rennard
University of Nebraska Medical Center, 985125 Nebraska Medical Center, Omaha, NE 68198, USA
Am J Respir Crit Care Med 175:926-34. 2007..Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung disease in which tumor necrosis factor-alpha is overexpressed and has been suggested to play a pathogenic role... - Inhaled corticosteroids and fracture risk: having our cake and eating it tooRobert Aris
Chest 127:5-7. 2005 - Improved sputum expectoration following a single dose of INS316 in patients with chronic bronchitisFred L Johnson
Inspire Pharmaceuticals, Inc, 4222 Emperor Boulevard, Suite 470, Durham, NC 27703 8466, USA
Chest 122:2021-9. 2002.... - Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvementRobert P Baughman
University of Cincinnati Medical Center, Cincinnati, OH 45267, USA
Am J Respir Crit Care Med 174:795-802. 2006..Evidence suggests that tumor necrosis factor (TNF)-alpha plays an important role in the pathophysiology of sarcoidosis...